IP Library › Granted Patent US 12,214,054
Granted Patent B2
US 12,214,054 · App. 15/779,633 · Granted Feb 4, 2025

Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use

Inventors: Charles A. Gersbach (Durham, NC); Jacqueline N. Robinson-Hamm (Durham, NC)
Assignee: Duke University
A61K48/005A61K31/7105A61K47/26A61K47/549A61K48/0016C12N15/102C12N15/113C12N15/80C12N15/8509C12Q1/68C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,054
App. No.
15/779,633
Granted
Feb 4, 2025
Kind
B2
Abstract

Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.

Claims (75)

1. A DNA targeting composition comprising a first gRNA molecule and a second gRNA molecule, wherein the first gRNA molecule and the second gRNA molecule are selected from the group consisting of:

(i) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 1, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 2;

(ii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(iii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(iv) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(v) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(vi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(vii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(viii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(ix) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(x) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15;

(xi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18; and

(xii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 41, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 42.

2. The DNA targeting composition of claim 1 , further comprising a Clustered Regularly Interspaced Short Palindromic Repeats associated (Cas) protein.

3. An isolated polynucleotide encoding the DNA targeting composition of claim 1 .

4. A vector encoding the DNA targeting composition of claim 1 .

5. A vector encoding:

(a) the DNA targeting composition of claim 1 , and

(b) at least one Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25).

6. The vector of claim 5 , wherein the vector is configured to form a first and a second double strand break in a first and a second intron flanking exon 51 of the human DMD gene.

7. The vector of claim 5 , wherein the vector is a viral vector.

8. The vector of claim 5 , wherein the vector comprises a tissue-specific promoter operably linked to the nucleotide sequence encoding the first gRNA molecule, and/or the second gRNA molecule, and/or the Cas9 molecule.

9. An isolated cell comprising the DNA targeting composition of claim 5 .

10. A kit comprising the vector of claim 5 .

11. A method of correcting a mutant dystrophin gene in a cell, the method comprising administering to a cell the gRNA of claim 3 .

12. A method of genome editing a mutant dystrophin gene in a subject, the method comprising administering to the subject a genome editing composition comprising the gRNA of claim 3 .

13. A method of treating a subject in need thereof having a mutant dystrophin gene, the method comprising administering to the subject the gRNA of claim 3 .

14. A composition for deleting a segment of a dystrophin gene comprising exon 51, the composition comprising:

(a) a first vector comprising a polynucleotide sequence encoding a first guide RNA (gRNA) molecule and a polynucleotide sequence encoding a first Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25), and

(b) a second vector comprising a polynucleotide sequence encoding a second gRNA molecule and a polynucleotide sequence encoding a second Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25),

wherein each of the first and second gRNA molecules have a targeting domain of 19 to 24 nucleotides in length, and wherein the first vector and second vector are configured to form a first and a second double strand break in a first intron and a second intron flanking exon 51 of the human DMD gene, respectively, thereby deleting a segment of the dystrophin gene comprising exon 51, and wherein the first gRNA molecule and the second gRNA molecule are selected from the group consisting of:

(i) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 1, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 2;

(ii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(iii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(iv) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(v) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(vi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(vii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(viii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(ix) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(x) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15;

(xi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18; and

(xii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 41, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 42.

15. A method of correcting a mutant dystrophin gene in a cell, comprising administering to the cell:

(a) a first vector comprising a polynucleotide sequence encoding a first guide RNA (gRNA) molecule and a polynucleotide sequence encoding a first Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25), and

(b) a second vector comprising a polynucleotide sequence encoding a second gRNA molecule and a polynucleotide sequence encoding a second Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25),

wherein each of the first gRNA and second gRNA molecules have a targeting domain of 19 to 24 nucleotides in length, wherein the vector is configured to form a first and a second double strand break in a first and a second intron flanking exon 51 of the human dystrophin gene, respectively, thereby deleting a segment of the dystrophin gene comprising exon 51, and wherein the first gRNA molecule and the second gRNA molecule are selected from the group consisting of:

(i) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 1, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 2;

(ii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(iii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(iv) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising s a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(v) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(vi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(vii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(viii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(ix) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(x) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15;

(xi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18; and

(xii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 41, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 42.

16. A method of treating a subject in need thereof having a mutant dystrophin gene, the method comprising administering to the subject:

(a) a first vector comprising a polynucleotide sequence encoding a first guide RNA (gRNA) molecule and a polynucleotide sequence encoding a first Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25), and

(b) a second vector comprising a polynucleotide sequence encoding a second gRNA molecule and a polynucleotide sequence encoding a second Cas9 molecule that recognizes a Protospacer Adjacent Motif (PAM) of either NNGRRT (SEQ ID NO: 24) or NNGRRV (SEQ ID NO: 25),

wherein each of the first gRNA and second gRNA molecules have a targeting domain of 19 to 24 nucleotides in length, wherein the vector is configured to form a first and a second double strand break in a first and a second intron flanking exon 51 of the human dystrophin gene, respectively, thereby deleting a segment of the dystrophin gene comprising exon 51, and wherein the first gRNA molecule and the second gRNA molecule are selected from the group consisting of:

(i) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 1, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 2;

(ii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(iii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(iv) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(v) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(vi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(vii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18;

(viii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 4;

(ix) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 19;

(x) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 14, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 15;

(xi) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 11, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 18; and

(xii) a first gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 41, and a second gRNA molecule comprising a targeting domain that is encoded by a polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 42.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 4, 2022
From: DUKE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 059852/0728 →
CONFIRMATORY LICENSE Recorded Sep 17, 2020
From: DUKE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 053802/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2018
From: GERSBACH, CHARLES A.; ROBINSON-HAMM, JACQUELINE N.
To: DUKE UNIVERSITY
Reel/Frame 045920/0246 →
Continuity (3)
Provisional Application 62330336 · May 2, 2016
Provisional Application 62260712 · Nov 30, 2015
Related Publication 20180353615A1 · Dec 13, 2018
References Cited (400)
US 3687808A · Merigan, Jr. · 1972 [cited by applicant]
US 4469863A · Ts'o et al. · 1984 [cited by applicant]
US 4476301A · Imbach et al. · 1984 [cited by applicant]
US 4501729A · Boucher et al. · 1985 [cited by applicant]
US 4554101A · Hopp · 1985 [cited by applicant]
US 4587044A · Miller et al. · 1986 [cited by applicant]
US 4605735A · Miyoshi et al. · 1986 [cited by applicant]
US 4667025A · Miyoshi et al. · 1987 [cited by applicant]
US 4737323A · Martin et al. · 1988 [cited by applicant]
US 4762779A · Snitman · 1988 [cited by applicant]
US 4789737A · Miyoshi et al. · 1988 [cited by applicant]
US 4824941A · Gordon et al. · 1989 [cited by applicant]
US 4828979A · Klevan et al. · 1989 [cited by applicant]
US 4835263A · Nguyen et al. · 1989 [cited by applicant]
US 4845205A · Huynh et al. · 1989 [cited by applicant]
US 4876335A · Yamane et al. · 1989 [cited by applicant]
US 4904582A · Tullis · 1990 [cited by applicant]
US 4948882A · Ruth · 1990 [cited by applicant]
US 4958013A · Letsinger · 1990 [cited by applicant]
US 5013830A · Ohsuka et al. · 1991 [cited by applicant]
US 5023243A · Tullis · 1991 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5082830A · Brakel et al. · 1992 [cited by applicant]
US 5109124A · Ramachandran et al. · 1992 [cited by applicant]
US 5112963A · Pieles et al. · 1992 [cited by applicant]
US 5118802A · Smith et al. · 1992 [cited by applicant]
US 5130302A · Spielvogel et al. · 1992 [cited by applicant]
US 5134066A · Rogers et al. · 1992 [cited by applicant]
US 5138045A · Cook et al. · 1992 [cited by applicant]
US 5149797A · Pederson et al. · 1992 [cited by applicant]
US 5166315A · Summerton et al. · 1992 [cited by applicant]
US 5175273A · Bischofberger et al. · 1992 [cited by applicant]
US 5177196A · Meyer et al. · 1993 [cited by applicant]
US 5185444A · Summerton et al. · 1993 [cited by applicant]
US 5188897A · Suhadolnik et al. · 1993 [cited by applicant]
US 5214134A · Weis et al. · 1993 [cited by applicant]
US 5214136A · Lin et al. · 1993 [cited by applicant]
US 5216141A · Benner · 1993 [cited by applicant]
US 5218105A · Cook et al. · 1993 [cited by applicant]
US 5219740A · Miller et al. · 1993 [cited by applicant]
US 5220007A · Pederson et al. · 1993 [cited by applicant]
US 5235033A · Summerton et al. · 1993 [cited by applicant]
US 5245022A · Weis et al. · 1993 [cited by applicant]
US 5254469A · Warren, III · 1993 [cited by applicant]
US 5256775A · Froehler · 1993 [cited by applicant]
US 5258506A · Urdea et al. · 1993 [cited by applicant]
US 5262536A · Hobbs, Jr. · 1993 [cited by applicant]
US 5264423A · Cohen et al. · 1993 [cited by applicant]
US 5264562A · Matteucci · 1993 [cited by applicant]
US 5264564A · Matteucci · 1993 [cited by applicant]
US 5272250A · Spielvogel et al. · 1993 [cited by applicant]
US 5276019A · Cohen et al. · 1994 [cited by applicant]
US 5278302A · Caruthers et al. · 1994 [cited by applicant]
US 5286717A · Cohen et al. · 1994 [cited by applicant]
US 5292873A · Rokita et al. · 1994 [cited by applicant]
US 5317098A · Shizuya et al. · 1994 [cited by applicant]
US 5321131A · Agrawal et al. · 1994 [cited by applicant]
US 5366878A · Pederson et al. · 1994 [cited by applicant]
US 5367066A · Urdea et al. · 1994 [cited by applicant]
US 5371241A · Brush · 1994 [cited by applicant]
US 5391723A · Priest · 1995 [cited by applicant]
US 5399676A · Froehler · 1995 [cited by applicant]
US 5403711A · Walder et al. · 1995 [cited by applicant]
US 5405938A · Summerton et al. · 1995 [cited by applicant]
US 5405939A · Suhadolnik et al. · 1995 [cited by applicant]
US 5414077A · Lin et al. · 1995 [cited by applicant]
US 5416203A · Letsinger · 1995 [cited by applicant]
US 5432272A · Benner · 1995 [cited by applicant]
US 5434257A · Matteucci et al. · 1995 [cited by applicant]
US 5451463A · Nelson et al. · 1995 [cited by applicant]
US 5453496A · Caruthers et al. · 1995 [cited by applicant]
US 5455233A · Spielvogel et al. · 1995 [cited by applicant]
US 5457187A · Gmeiner et al. · 1995 [cited by applicant]
US 5459255A · Cook et al. · 1995 [cited by applicant]
US 5466677A · Baxter et al. · 1995 [cited by applicant]
US 5470967A · Huie et al. · 1995 [cited by applicant]
US 5476925A · Letsinger et al. · 1995 [cited by applicant]
US 5478745A · Samulski et al. · 1995 [cited by applicant]
US 5484908A · Froehler et al. · 1996 [cited by applicant]
US 5486603A · Buhr · 1996 [cited by applicant]
US 5489677A · Sanghvi et al. · 1996 [cited by applicant]
US 5491133A · Walder et al. · 1996 [cited by applicant]
US 5502177A · Matteucci et al. · 1996 [cited by applicant]
US 5510473A · Camerini-otero et al. · 1996 [cited by applicant]
US 5510475A · Agrawal et al. · 1996 [cited by applicant]
US 5512439A · Horner et al. · 1996 [cited by applicant]
US 5512667A · Reed et al. · 1996 [cited by applicant]
US 5514785A · Van Ness et al. · 1996 [cited by applicant]
US 5519126A · Hecht · 1996 [cited by applicant]
US 5525465A · Haralambidis et al. · 1996 [cited by applicant]
US 5525711A · Hawkins et al. · 1996 [cited by applicant]
US 5536821A · Agrawal et al. · 1996 [cited by applicant]
US 5541306A · Agrawal et al. · 1996 [cited by applicant]
US 5541307A · Cook et al. · 1996 [cited by applicant]
US 5541313A · Ruth · 1996 [cited by applicant]
US 5545730A · Urdea et al. · 1996 [cited by applicant]
US 5550111A · Suhadolnik et al. · 1996 [cited by applicant]
US 5552538A · Urdea et al. · 1996 [cited by applicant]
US 5552540A · Haralambidis · 1996 [cited by applicant]
US 5561225A · Maddry et al. · 1996 [cited by applicant]
US 5563253A · Agrawal et al. · 1996 [cited by applicant]
US 5565350A · Kmiec · 1996 [cited by applicant]
US 5565552A · Magda et al. · 1996 [cited by applicant]
US 5567810A · Weis et al. · 1996 [cited by applicant]
US 5571799A · Tkachuk et al. · 1996 [cited by applicant]
US 5574142A · Meyer et al. · 1996 [cited by applicant]
US 5578717A · Urdea et al. · 1996 [cited by applicant]
US 5578718A · Cook et al. · 1996 [cited by applicant]
US 5580731A · Chang et al. · 1996 [cited by applicant]
US 5585481A · Arnold, Jr. et al. · 1996 [cited by applicant]
US 5587361A · Cook et al. · 1996 [cited by applicant]
US 5587371A · Sessler et al. · 1996 [cited by applicant]
US 5587469A · Cook et al. · 1996 [cited by applicant]
US 5591584A · Chang et al. · 1997 [cited by applicant]
US 5593972A · Weiner et al. · 1997 [cited by applicant]
US 5595726A · Magda et al. · 1997 [cited by applicant]
US 5596086A · Matteucci et al. · 1997 [cited by applicant]
US 5596091A · Switzer · 1997 [cited by applicant]
US 5597696A · Linn et al. · 1997 [cited by applicant]
US 5599923A · Sessler et al. · 1997 [cited by applicant]
US 5599928A · Hemmi et al. · 1997 [cited by applicant]
US 5602240A · De Mesmaeker et al. · 1997 [cited by applicant]
US 5608046A · Cook et al. · 1997 [cited by applicant]
US 5610289A · Cook et al. · 1997 [cited by applicant]
US 5614617A · Cook et al. · 1997 [cited by applicant]
US 5618704A · Sanghvi et al. · 1997 [cited by applicant]
US 5623065A · Cook et al. · 1997 [cited by applicant]
US 5623070A · Cook et al. · 1997 [cited by applicant]
US 5625050A · Beaton et al. · 1997 [cited by applicant]
US 5633360A · Bischofberger et al. · 1997 [cited by applicant]
US 5652355A · Metelev et al. · 1997 [cited by applicant]
US 5652356A · Agrawal · 1997 [cited by applicant]
US 5663312A · Chaturvedula et al. · 1997 [cited by applicant]
US 5677437A · Teng et al. · 1997 [cited by applicant]
US 5677439A · Weis et al. · 1997 [cited by applicant]
US 5681941A · Cook et al. · 1997 [cited by applicant]
US 5688941A · Cook et al. · 1997 [cited by applicant]
US 5700922A · Cook et al. · 1997 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5719262A · Buchardt et al. · 1998 [cited by applicant]
US 5750692A · Cook et al. · 1998 [cited by applicant]
US 5773700A · Van Grinsven et al. · 1998 [cited by applicant]
US 5962428A · Carrano et al. · 1999 [cited by applicant]
US 6140081A · Barbas · 2000 [cited by applicant]
US 6207453B1 · Maass et al. · 2001 [cited by applicant]
US 6268490B1 · Imanishi et al. · 2001 [cited by applicant]
US 6287860B1 · Monia et al. · 2001 [cited by applicant]
US 6453242B1 · Eisenberg et al. · 2002 [cited by applicant]
US 6462254B1 · Vernachio et al. · 2002 [cited by applicant]
US 6534261B1 · Cox, III et al. · 2003 [cited by applicant]
US 6734291B2 · Kochkine et al. · 2004 [cited by applicant]
US 6770748B2 · Imanishi et al. · 2004 [cited by applicant]
US 6794499B2 · Wengel et al. · 2004 [cited by applicant]
US 7034133B2 · Wengel et al. · 2006 [cited by applicant]
US 7053207B2 · Wengel · 2006 [cited by applicant]
US 7060809B2 · Wengel et al. · 2006 [cited by applicant]
US 7074596B2 · Darzynkiewicz et al. · 2006 [cited by applicant]
US 7084125B2 · Wengel · 2006 [cited by applicant]
US 7449561B1 · Sommer et al. · 2008 [cited by applicant]
US 7572582B2 · Wengel et al. · 2009 [cited by applicant]
US 7728118B2 · Wood et al. · 2010 [cited by applicant]
US 7745651B2 · Heyes et al. · 2010 [cited by applicant]
US 7799565B2 · Maclachlan et al. · 2010 [cited by applicant]
US 8278036B2 · Kariko et al. · 2012 [cited by applicant]
US 8450107B1 · Zhang et al. · 2013 [cited by applicant]
US 8586526B2 · Gregory et al. · 2013 [cited by applicant]
US 8889356B2 · Zhang · 2014 [cited by applicant]
US 9139554B2 · Hope et al. · 2015 [cited by applicant]
US 9458205B2 · Gregory et al. · 2016 [cited by applicant]
US 9890364B2 · Joung et al. · 2018 [cited by applicant]
US 10266850B2 · Doudna et al. · 2019 [cited by applicant]
US 11421251B2 · Gersbach et al. · 2022 [cited by applicant]
US 11427817B2 · Josephs et al. · 2022 [cited by applicant]
US 20020160940A1 · Case et al. · 2002 [cited by applicant]
US 20040142025A1 · Maclachlan et al. · 2004 [cited by applicant]
US 20040175727A1 · Draghia-Akli et al. · 2004 [cited by applicant]
US 20040192593A1 · Draghia-Akli et al. · 2004 [cited by applicant]
US 20040204345A1 · Case et al. · 2004 [cited by applicant]
US 20060068395A1 · Wood et al. · 2006 [cited by applicant]
US 20060211647A1 · Khan · 2006 [cited by applicant]
US 20070042031A1 · Maclachlan et al. · 2007 [cited by applicant]
US 20070042462A1 · Hildinger · 2007 [cited by applicant]
US 20070059795A1 · Moore et al. · 2007 [cited by applicant]
US 20070185042A1 · Tsai et al. · 2007 [cited by applicant]
US 20070192880A1 · Muyan et al. · 2007 [cited by applicant]
US 20080070299A1 · Wood et al. · 2008 [cited by applicant]
US 20080090291A1 · Wood et al. · 2008 [cited by applicant]
US 20090018031A1 · Trinklein et al. · 2009 [cited by applicant]
US 20100035968A1 · Rasmussen et al. · 2010 [cited by applicant]
US 20100076057A1 · Sontheimer et al. · 2010 [cited by applicant]
US 20100261175A1 · Rasmussen et al. · 2010 [cited by applicant]
US 20100267018A1 · Wengel et al. · 2010 [cited by applicant]
US 20110145940A1 · Voytas et al. · 2011 [cited by applicant]
US 20110197290A1 · Fahrenkrug et al. · 2011 [cited by applicant]
US 20110263682A1 · De Kimpe et al. · 2011 [cited by applicant]
US 20110301073A1 · Gregory et al. · 2011 [cited by applicant]
US 20120195917A1 · Sahin et al. · 2012 [cited by applicant]
US 20120207744A1 · Mendlein et al. · 2012 [cited by applicant]
US 20130274129A1 · Katzen et al. · 2013 [cited by applicant]
US 20140179006A1 · Zhang · 2014 [cited by applicant]
US 20140234975A1 · Silva et al. · 2014 [cited by applicant]
US 20140295557A1 · Joung et al. · 2014 [cited by applicant]
US 20140356956A1 · Church et al. · 2014 [cited by applicant]
US 20150024499A1 · Brouns et al. · 2015 [cited by applicant]
US 20150031089A1 · Lindstrom · 2015 [cited by applicant]
US 20150044772A1 · Zhao · 2015 [cited by applicant]
US 20150045413A1 · De Visser et al. · 2015 [cited by applicant]
US 20150056705A1 · Conway et al. · 2015 [cited by applicant]
US 20150079064A1 · Gersbach et al. · 2015 [cited by applicant]
US 20150159178A1 · Green et al. · 2015 [cited by applicant]
US 20150225717A1 · Lee et al. · 2015 [cited by applicant]
US 20150252358A1 · Maeder et al. · 2015 [cited by applicant]
US 20160002634A1 · Sazani et al. · 2016 [cited by applicant]
US 20160040189A1 · Kennedy et al. · 2016 [cited by applicant]
US 20160058889A1 · Olson et al. · 2016 [cited by applicant]
US 20160177278A1 · Wolfe et al. · 2016 [cited by applicant]
US 20160199419A1 · Miura · 2016 [cited by applicant]
US 20160201089A1 · Gersbach et al. · 2016 [cited by applicant]
US 20160281166A1 · Bhattacharjee et al. · 2016 [cited by applicant]
US 20160354487A1 · Zhang et al. · 2016 [cited by applicant]
US 20170002316A1 · Gascón Jiménez et al. · 2017 [cited by applicant]
US 20170198308A1 · Qi et al. · 2017 [cited by applicant]
US 20170204407A1 · Gilbert et al. · 2017 [cited by applicant]
US 20170283831A1 · Zhang et al. · 2017 [cited by applicant]
US 20170362635A1 · Chamberlain et al. · 2017 [cited by applicant]
US 20180073012A1 · Liu et al. · 2018 [cited by applicant]
US 20180127780A1 · Liu et al. · 2018 [cited by applicant]
US 20180135109A1 · Jayaram et al. · 2018 [cited by applicant]
US 20180201951A1 · Guilak et al. · 2018 [cited by applicant]
US 20180237771A1 · Kim et al. · 2018 [cited by applicant]
US 20180251735A1 · Ko · 2018 [cited by applicant]
US 20180271069A1 · Min et al. · 2018 [cited by applicant]
US 20180280539A1 · Debs et al. · 2018 [cited by applicant]
US 20180305689A1 · Sætrom et al. · 2018 [cited by applicant]
US 20180305704A1 · Zhang · 2018 [cited by applicant]
US 20180305719A1 · Perez-Pinera et al. · 2018 [cited by applicant]
US 20180319850A1 · Payne et al. · 2018 [cited by applicant]
US 20180320197A1 · Gersbach et al. · 2018 [cited by applicant]
US 20180327740A1 · Gifford et al. · 2018 [cited by applicant]
US 20180334685A1 · Yeo et al. · 2018 [cited by applicant]
US 20190032049A1 · Naldini et al. · 2019 [cited by applicant]
US 20190038776A1 · Pyle et al. · 2019 [cited by applicant]
US 20190048337A1 · Hsu · 2019 [cited by examiner]
US 20190062790A1 · Doudna et al. · 2019 [cited by applicant]
US 20190078119A1 · Wilson et al. · 2019 [cited by applicant]
US 20190106710A1 · Zhang et al. · 2019 [cited by applicant]
US 20190127713A1 · Gersbach et al. · 2019 [cited by applicant]
US 20190134221A1 · Bumcrot et al. · 2019 [cited by applicant]
US 20190151476A1 · Gersbach et al. · 2019 [cited by applicant]
US 20190183932A1 · Mackall et al. · 2019 [cited by applicant]
US 20190201402A1 · Jiang et al. · 2019 [cited by applicant]
US 20190264232A1 · Hou et al. · 2019 [cited by applicant]
US 20190374655A1 · Kabadi et al. · 2019 [cited by applicant]
US 20200002731A1 · Frendewey et al. · 2020 [cited by applicant]
US 20200056206A1 · Tremblay et al. · 2020 [cited by applicant]
US 20200123533A1 · Wang et al. · 2020 [cited by applicant]
US 20200216549A1 · Fukumura et al. · 2020 [cited by applicant]
US 20200216810A1 · Metelitsa et al. · 2020 [cited by applicant]
US 20200275641A1 · Min et al. · 2020 [cited by applicant]
US 20210322577A1 · Lande et al. · 2021 [cited by applicant]
US 20220098561A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220177879A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220184229A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220195406A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220305141A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220307015A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220364124A1 · Gersbach et al. · 2022 [cited by applicant]
US 20220396790A1 · Gersbach et al. · 2022 [cited by applicant]
US 20230032846A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230047669A1 · Josephs et al. · 2023 [cited by applicant]
US 20230201375A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230348870A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230349888A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230383270A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230383297A1 · Gersbach et al. · 2023 [cited by applicant]
US 20230392132A1 · Gersbach et al. · 2023 [cited by applicant]
US 20240026352A1 · Gersbach et al. · 2024 [cited by applicant]
US 20240052328A1 · Kwon et al. · 2024 [cited by applicant]
US 20240058425A1 · Gersbach et al. · 2024 [cited by applicant]
US 20240067968A1 · Cosgrove et al. · 2024 [cited by applicant]
AU 2022318664A1 · 2024 [cited by applicant]
CA 2749305A1 · 2010 [cited by applicant]
CA 2981508A1 · 2016 [cited by applicant]
CA 3086885A1 · 2019 [cited by applicant]
CA 3101477A1 · 2019 [cited by applicant]
EP 3009511A2 · 2016 [cited by applicant]
EP 3199632A1 · 2017 [cited by applicant]
EP 3712272A1 · 2020 [cited by applicant]
EP 3209783B1 · 2021 [cited by applicant]
EP 3995584A1 · 2022 [cited by applicant]
JP 2013509159A · 2013 [cited by applicant]
JP 2015534817A · 2015 [cited by applicant]
JP 2016521452A · 2016 [cited by applicant]
JP 2016521975A · 2016 [cited by applicant]
JP 2016523082A · 2016 [cited by applicant]
KR 20190134673A · 2019 [cited by applicant]
WO 199118114A1 · 1991 [cited by applicant]
WO WO1992000387A1 · 1992 [cited by applicant]
WO WO1993007883A1 · 1993 [cited by applicant]
WO WO1993024640A2 · 1993 [cited by applicant]
WO WO1994016737A1 · 1994 [cited by applicant]
WO WO1998053058A1 · 1998 [cited by applicant]
WO WO1998053059A1 · 1998 [cited by applicant]
WO WO1998053060A1 · 1998 [cited by applicant]
WO WO2000028004A1 · 2000 [cited by applicant]
WO 2001083793A2 · 2001 [cited by applicant]
WO WO2001083783A2 · 2001 [cited by applicant]
WO WO2001092551A2 · 2001 [cited by applicant]
WO WO2002016536A1 · 2002 [cited by applicant]
WO WO2003016496A2 · 2003 [cited by applicant]
WO WO2003072788A1 · 2003 [cited by applicant]
WO WO2007019301A2 · 2007 [cited by applicant]
WO WO2008006028A2 · 2008 [cited by applicant]
WO WO2008070859A2 · 2008 [cited by applicant]
WO WO2010075424A2 · 2010 [cited by applicant]
WO WO2010144740A1 · 2010 [cited by applicant]
WO WO2011036640A2 · 2011 [cited by applicant]
WO WO2011154427A1 · 2011 [cited by applicant]
WO WO2012136476A1 · 2012 [cited by applicant]
WO WO2013098244A1 · 2013 [cited by applicant]
WO WO2013163628A2 · 2013 [cited by applicant]
WO WO2014018423A2 · 2014 [cited by applicant]
WO WO2014059255A1 · 2014 [cited by applicant]
WO 2014081855A1 · 2014 [cited by applicant]
WO WO2014065596A1 · 2014 [cited by applicant]
WO 2014093595A1 · 2014 [cited by applicant]
WO 2014093622A2 · 2014 [cited by applicant]
WO 2014093712A1 · 2014 [cited by applicant]
WO 2014099744A1 · 2014 [cited by applicant]
WO WO2014089290A1 · 2014 [cited by applicant]
WO WO2014093479A1 · 2014 [cited by applicant]
WO WO2014093709A1 · 2014 [cited by applicant]
WO WO2014144592A2 · 2014 [cited by applicant]
WO 2014197568A2 · 2014 [cited by applicant]
WO WO2014197748A2 · 2014 [cited by applicant]
WO WO2014204726A1 · 2014 [cited by applicant]
WO WO2015006747A2 · 2015 [cited by applicant]
WO 2015021457A2 · 2015 [cited by applicant]
WO 2015035139A2 · 2015 [cited by applicant]
WO WO2015035136A2 · 2015 [cited by applicant]
WO WO2015048690A1 · 2015 [cited by applicant]
WO 2015070083A1 · 2015 [cited by applicant]
WO 2015089462A1 · 2015 [cited by applicant]
WO WO2015089427A1 · 2015 [cited by applicant]
WO WO2015155686A2 · 2015 [cited by applicant]
WO WO2015161276A2 · 2015 [cited by applicant]
WO 2015195621A1 · 2015 [cited by applicant]
WO 2016011080A2 · 2016 [cited by applicant]
WO WO2016011070A2 · 2016 [cited by applicant]
WO WO2016049258A2 · 2016 [cited by applicant]
WO WO2016063264A1 · 2016 [cited by applicant]
WO 2016070070A1 · 2016 [cited by applicant]
WO WO2016081924A1 · 2016 [cited by applicant]
WO WO2016114972A1 · 2016 [cited by applicant]
WO WO2016123578A1 · 2016 [cited by applicant]
WO WO2016130600A2 · 2016 [cited by applicant]
WO WO2016161380A1 · 2016 [cited by applicant]
WO 2016205613A1 · 2016 [cited by applicant]
WO WO2016187717A1 · 2016 [cited by applicant]
WO 2017016915A1 · 2017 [cited by applicant]
WO WO2017049266A2 · 2017 [cited by applicant]
WO WO2017049407A1 · 2017 [cited by applicant]
WO WO2017070632A2 · 2017 [cited by applicant]
WO WO2017072590A1 · 2017 [cited by applicant]
WO WO2017075478A2 · 2017 [cited by applicant]
WO 2017139505A2 · 2017 [cited by applicant]
WO WO2017165859A1 · 2017 [cited by applicant]
WO 2017180976A1 · 2017 [cited by applicant]
WO WO2017180915A2 · 2017 [cited by applicant]
WO 2017193029A3 · 2017 [cited by applicant]
WO 2018002812A1 · 2018 [cited by applicant]
WO 2018005805A1 · 2018 [cited by applicant]
WO 2018017483A1 · 2018 [cited by applicant]
WO WO2018013932A1 · 2018 [cited by applicant]
WO WO2018017751A1 · 2018 [cited by applicant]
WO WO2018035388A1 · 2018 [cited by applicant]
WO WO2018035495A1 · 2018 [cited by applicant]
WO 2018039145A1 · 2018 [cited by applicant]
WO 2018098480A1 · 2018 [cited by applicant]
WO WO2018081504A1 · 2018 [cited by applicant]
WO 2018107003A1 · 2018 [cited by applicant]
WO WO2018129296A1 · 2018 [cited by applicant]
WO 2018162702A1 · 2018 [cited by applicant]
WO 2018179578A1 · 2018 [cited by applicant]
WO WO2018191388A1 · 2018 [cited by applicant]
WO 2019009682A2 · 2019 [cited by applicant]
WO 2019023291A2 · 2019 [cited by applicant]
WO WO2019002590A1 · 2019 [cited by applicant]
WO WO2019036599A1 · 2019 [cited by applicant]
WO 2019046755A1 · 2019 [cited by applicant]
WO WO2019067786A1 · 2019 [cited by applicant]
WO WO2019077001A1 · 2019 [cited by applicant]
WO WO2019079514A1 · 2019 [cited by applicant]
WO 2019084050A1 · 2019 [cited by applicant]
WO WO2019092505A1 · 2019 [cited by applicant]
WO 2019113472A1 · 2019 [cited by applicant]
WO 2019123014A1 · 2019 [cited by applicant]
WO 2019136216A1 · 2019 [cited by applicant]
WO 2019204750A1 · 2019 [cited by applicant]
WO 2019213626A1 · 2019 [cited by applicant]
Cited By (2)
US 12,428,631 US 12,629,428